Focus on: Muscle Invasive Bladder Cancer (MIBC)

Based on the documented need from our 2025 Bladder Cancer Global Needs Assessment, the American Urological Association (AUA) is offering a new 90-minute CME educational activity to further address the identified educational gaps and barriers in advanced bladder cancer. This extended format allows for a deeper dive into Muscle Invasive Bladder Cancer (MIBC), to update urologists on the latest advancements in treatment.

Learning Objectives:
After participating in this CME activity, participants will be able to:
1. Evaluate limitations in the current MIBC treatment landscape including patient outcomes and gaps in available systemic therapies to identify individuals with limited or no effective treatment options and enhance clinical decision-making.
2. Interpret the mechanisms of action and clinical data supporting antibody-drug conjugates (ADCs) to determine their potential role in addressing unmet therapeutic needs in patients with MIBC who are ineligible for traditional treatment pathways.
3. Incorporate evidence-based perioperative systemic treatment strategies including neoadjuvant and adjuvant approaches into patient care algorithms to improve pathologic response rates and survival outcomes in MIBC.
4. Apply best practices for managing and mitigating adverse events associated with emerging systemic and perioperative therapies to optimize treatment adherence and patient safety in the MIBC setting.
5. Implement strategies for effective communication, multidisciplinary care coordination, and shared decision-making between urologists, medical oncologists, and patients to improve treatment alignment and patient-centered outcomes in MIBC.